Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy.

Journal: Journal for immunotherapy of cancer •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Arias V, Clubb JH, Kudling TV, et al. (2026). "Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy.". Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-016430